Income Statement
The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.
Cytokinetics Inc., consolidated income statement
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
The financial data presents several notable trends and shifts over the five-year period. Overall, revenues show a fluctuating but upward trajectory, increasing substantially from approximately $31.5 million in 2018 to nearly $94.6 million in 2022. This growth is primarily driven by sharp increases in license revenues and the realization of a significant revenue participation right purchase agreement in 2022, which alone contributed $87.0 million that year. Research and development revenues have steadily declined from $26.4 million in 2018 to $6.6 million in 2022, while milestone revenues appear intermittently, peaking at $5.0 million in 2021 before dropping to $1.0 million in 2022.
- Research and Development Expenses
- These expenses have consistently increased year over year, rising from $89.1 million in 2018 to $240.8 million in 2022. The accelerated increase especially between 2020 and 2022 indicates intensified investment or escalating costs in this area.
- General and Administrative Expenses
- General and administrative costs have more than quintupled during the period, climbing from $31.3 million in 2018 to $178.0 million in 2022. The marked growth in these expenses aligns with the overall increase in operating expenses.
- Operating Expenses and Loss
- Operating expenses escalate in tandem with research and administrative costs, totaling $418.8 million in 2022 compared to $120.4 million in 2018. This surge corresponds with a substantial widening of the operating loss, which deepened significantly from $88.9 million in 2018 to $324.2 million in 2022, signifying challenges in offsetting rising costs with revenue gains.
- Interest and Financial Items
- Interest expense displays an upward trend, multiplying from $3.8 million in 2018 to $19.4 million in 2022. Notably, a loss on debt settlement of $24.9 million is recorded only in 2022. Non-cash interest expense related to liabilities from revenue participation rights shows volatility, declining after 2020 but rising again sharply in 2022. Interest and other net income also fluctuate, peaking at $11.3 million in 2022, indicating varying levels of income from non-operating activities.
- Net Loss and Pre-tax Loss
- The net loss mirrors the trend in operating losses, expanding steadily year by year to reach nearly $389.0 million by the end of 2022. This growing loss before income tax provision reflects the cumulative impact of increasing expenses outweighing revenue growth.
In summary, despite significant increases in total revenues driven by licensing incomes and one-time revenue participation agreement realization, the company faces escalating operational costs, particularly in research and development and administrative functions, causing substantial operating and net losses. Financial expenses have also risen, with occasional one-time charges affecting results. The data suggests a focus on heavy investment phases and a challenging environment in terms of profitability, warranting continued monitoring of expense management and revenue diversification strategies.